Navigation Links
Differing reactions to anti clotting drugs may be due to genetic variation.,,

People who take anti clotting drugs like warfarin may react differently to the drug because of their genetic makeup.//

A sizable population of the world takes anti clotting medications in the event of heart attacks, stroke or major surgery to check harmful clotting of blood. However the difference in the reactions to the drugs have foxed the physicians for long and made it difficult to standardize the proper dosage of the drug. A little change in dose often may result in more reactions to blood flow.

Researchers of University of Washington in Seattle had discovered the variations in a gene that alters the way people respond to blood clotting medications. The gene encodes the CYP2C9 enzyme that metabolizes the anti clot drug and thus accounts for almost 10% variations of the reactions to the drug warfarin.

When are patients are tested for variations in reactions to medications, the tests mostly concentrate on the sex, age, weight and medical history of the patients. It may take months of visits to the physicians to find out the right dose for the patient even then. Genetic variations are often not considered here. The new research will emphasize the study of people’s reaction to medications and their genetic coding, also called pharmacogenetics.

Reference: National Institutes of Health, news release, June 2005
'"/>




Page: 1

Related medicine news :

1. Differing Ideas on Management of Alzheimer’s diseas
2. ZYBAN, The smoking cessation drug marked for its adverse reactions
3. Lupin flour may cause peanut allergy like reactions
4. Arsenic poisoning reactions can be traced to genes
5. stents Result in allergic reactions
6. Aspirin surpasses Modern Anti-clotting Drugs
7. Enduring anti-clotting treatment avails heart patients
8. Treatment over a longer period for blood clotting
9. Gum disease may be caused by blood clotting gene
10. Anlene brand of milk products will carry warnings about blood-clotting risks
11. Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults are ... bariatric surgery has received increased attention in recent years, as an article ... to weight loss, most people are familiar with the basic requirements of maintaining a ...
(Date:5/27/2016)... ... , ... W.S. Badger Co. Inc ., the maker of certified organic ... one of the best small businesses for new dads by Fatherly, the digital lifestyle ... providing progressive benefits to new parents on the organization’s 2016 Best Places to ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a ... as a society can control and change. , As nearly 795,000 Americans suffering from ... within the United States. Plus, with an estimated 129,000 of these people dying from ...
(Date:5/27/2016)... Killeen, Texas (PRWEB) , ... May 27, 2016 , ... ... with satisfying Army body fat composition regulations. This is the first time that ... are normally screened at least every six months to ensure they meet the prescribed ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology: